According to Eagle Pharmaceuticals
's latest financial reports the company's current revenue (TTM ) is HK$2.02 Billion. In 2022 the company made a revenue of HK$2.47 Billion an increase over the revenue in the year 2021 that were of HK$1.33 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | HK$2.01 B | -18.4% |
2022 | HK$2.47 B | 84.93% |
2021 | HK$1.33 B | -8.12% |
2020 | HK$1.45 B | -4.57% |
2019 | HK$1.52 B | -8.67% |
2018 | HK$1.67 B | -9.68% |
2017 | HK$1.84 B | 25.86% |
2016 | HK$1.46 B | 186.25% |
2015 | HK$0.51 B | 244.55% |
2014 | HK$0.14 B | 8.62% |
2013 | HK$0.13 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | HK$701.18 B | 34,584.78% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | HK$318.57 B | 15,658.66% | ๐ฌ๐ง UK |
![]() Novartis NVS | HK$417.75 B | 20,564.65% | ๐จ๐ญ Switzerland |
![]() Teva Pharmaceutical Industries TEVA | HK$130.41 B | 6,351.15% | ๐ฎ๐ฑ Israel |
![]() Amgen AMGN | HK$267.86 B | 13,150.19% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | HK$384.64 B | 18,926.60% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | HK$373.90 B | 18,395.75% | ๐บ๐ธ USA |